Invitae (NYSE:NVTA) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Invitae (NYSE:NVTA) in a research note published on Tuesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Invitae Price Performance

Shares of Invitae stock opened at $0.00 on Tuesday. The company has a market capitalization of $80,103.00, a PE ratio of 0.00 and a beta of 1.59. Invitae has a 52 week low of $0.02 and a 52 week high of $0.02.

Institutional Trading of Invitae

Several institutional investors and hedge funds have recently modified their holdings of NVTA. SG Americas Securities LLC grew its holdings in shares of Invitae by 90.7% in the fourth quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 43,717 shares in the last quarter. Prosperity Wealth Management Inc. bought a new position in shares of Invitae in the fourth quarter valued at approximately $144,000. Finally, Vestmark Advisory Solutions Inc. bought a new position in shares of Invitae in the fourth quarter valued at approximately $526,000. 61.28% of the stock is owned by hedge funds and other institutional investors.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.